[HTML][HTML] Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses
J Chen, F Xu, X Ruan, J Sun, Y Zhang, H Zhang… - …, 2023 - thelancet.com
Background Identifying new drug targets for inflammatory bowel disease (IBD) is urgently
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses
J Chen, F Xu, X Ruan, J Sun, Y Zhang… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Identifying new drug targets for inflammatory bowel disease (IBD) is urgently
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
[HTML][HTML] Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses
J Chen, F Xu, X Ruan, J Sun, Y Zhang, H Zhang… - eBioMedicine, 2023 - Elsevier
Background Identifying new drug targets for inflammatory bowel disease (IBD) is urgently
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses
J Chen, F Xu, X Ruan, J Sun, Y Zhang, H Zhang… - …, 2023 - diva-portal.org
Background: Identifying new drug targets for inflammatory bowel disease (IBD) is urgently
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
[PDF][PDF] Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses
X Li, S Yuan - 2023 - researchgate.net
Background Identifying new drug targets for inflammatory bowel disease (IBD) is urgently
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses.
J Chen, F Xu, X Ruan, J Sun, Y Zhang, H Zhang… - Ebiomedicine, 2023 - europepmc.org
Background Identifying new drug targets for inflammatory bowel disease (IBD) is urgently
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
[HTML][HTML] Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses
J Chen, F Xu, X Ruan, J Sun, Y Zhang, H Zhang… - eBioMedicine, 2023 - ncbi.nlm.nih.gov
Background Identifying new drug targets for inflammatory bowel disease (IBD) is urgently
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
[PDF][PDF] Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses
X Li, S Yuan - 2023 - researchgate.net
Background Identifying new drug targets for inflammatory bowel disease (IBD) is urgently
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses.
J Chen, F Xu, X Ruan, J Sun, Y Zhang, H Zhang… - Ebiomedicine, 2023 - europepmc.org
Background Identifying new drug targets for inflammatory bowel disease (IBD) is urgently
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …
needed. The proteome is a major source of therapeutic targets. We conducted a proteome …